CytoPathfinder
CytoPathfinder develops and commercializes solid-phase transfection technology to simplify and improve gene function analysis for drug discovery and cell therapy research.
Private Company
Funding information not available
AI Company Overview
CytoPathfinder develops and commercializes solid-phase transfection technology to simplify and improve gene function analysis for drug discovery and cell therapy research.
Technology Platform
Solid-phase transfection technology that pre-coats nucleic acids, transfection reagents, and patented accelerator compounds on microplate surfaces, enabling simplified and efficient gene delivery to difficult-to-transfect cells including primary cells and stem cells.
Opportunities
Risk Factors
Competitive Landscape
Competes against major transfection reagent providers like Thermo Fisher and Promega, but differentiates through solid-phase technology that simplifies protocols and improves efficiency with difficult primary cells and stem cells.